 |
|
Scientists identify interacting proteins key to melanoma development, treatment
May 07, 2008Researchers have discovered how a mole develops into melanoma by showing the interaction of two key proteins involved in 60-70 percent of tumors. The Penn State scientists also demonstrate that therapeutic targeting of these proteins is necessary for drugs to effectively treat this deadly form of cancer.
"We have shown that when two proteins - (V600E)B-Raf and Akt3 - communicate with one another in a mole, they cooperate leading to the development of melanoma," said Gavin Robertson, lead author and associate professor of pharmacology, pathology and dermatology, and director of the Foreman Foundation Melanoma Therapeutics Program at the Penn State College of Medicine Cancer Institute. "We have also shown that effective therapies for melanoma need to target both these proteins, which essentially eliminates the tumors."
Melanoma is the most deadly form of skin cancer because it metastasizes or moves around the body so quickly. In general, people with advanced-stage disease only have months to live. Currently, melanoma kills one person every hour in the U.S., and is predicted to affect one in 50 people by 2010. In recent years, researchers have zeroed in on two key genes - B-Raf and Akt3 - that cause this deadly cancer, and which could be important targets in the treatment of melanoma.
B-Raf is the most mutated gene in melanoma. The mutant protein, (V600E)B-Raf, produced by this gene is important in helping mole cells survive and grow but it is unable to form melanomas on its own. Nearly 90 percent of all moles have the mutant protein but it is not fully clear why only some of them turn into melanomas.
Robertson and his colleagues have found that a second protein - produced by Akt3 - regulates the activity of the mutated B-Raf, which aids the development of melanoma.
"What we have found is a second event that is necessary for melanomas to develop," added Robertson, whose findings are reported in the May 1 issue of the journal Cancer Research.
While comparing proteins within normal moles and human melanoma cells, the Penn State researchers noticed that the two proteins were communicating with one another only among melanoma cells but not among normal cells.
When the Akt3 protein was put into cells in conjunction with the mutant B-Raf gene, they were better able to form melanomas compared to cells just containing the mutant B-Raf gene.
"This tells us that you can have a mole but it cannot turn into melanoma without the presence of the Akt3 protein," explained Robertson.
While it is still unclear what brings the B-Raf and Akt3 proteins together, the Penn State researchers say they now have a better understanding of how these two proteins interact to cause melanoma.
The initial mutation of the B-Raf gene helps to create moles, but high levels of B-Raf activity due to the mutation prevents the cells from becoming a melanoma. It is only when the Akt3 protein is present in those cells and communicates with B-Raf that it lower its activity, thereby creating favorable conditions within the mole for cells to multiply, and allow them to turn into a melanoma.
Robertson said the discovery could pave the way for newer and more effective treatments for melanoma.
"We have shown that if we target the two proteins separately, it somewhat inhibits the development of tumors but if we target them together, the development of tumors gets inhibited significantly," he added. "It validates these proteins as key targets for effective melanoma therapy."
Robertson envisions that future physicians could look at blood samples from melanoma patients containing melanoma cells and determine whether the two proteins are in their cells. The patients could then receive drugs that target these proteins to more effectively treat their disease. It would be personalized cancer treatment that would be more effective and less toxic with fewer side effects, the Penn State researcher explained.
"In the search for a cure for melanoma, we are now closer because we know that we need to target these two proteins in order to have a dramatic impact on the development of melanoma," Robertson added.
For patients, this means that in the future, some new drug could target these proteins to treat advanced disease or be added to sunscreen lotion, for instance, that would prevent Akt3 functioning in the cell. It would not only help control a tumor, but also prevent one as well.
Penn State
B-Raf is the most mutated gene in melanoma. The mutant protein, (V600E)B-Raf, produced by this gene is important in helping mole cells survive and grow but it is unable to form melanomas on its own. Nearly 90 percent of all moles have the mutant protein but it is not fully clear why only some of them turn into melanomas.
Robertson and his colleagues have found that a second protein - produced by Akt3 - regulates the activity of the mutated B-Raf, which aids the development of melanoma.
"What we have found is a second event that is necessary for melanomas to develop," added Robertson, whose findings are reported in the May 1 issue of the journal Cancer Research.
While comparing proteins within normal moles and human melanoma cells, the Penn State researchers noticed that the two proteins were communicating with one another only among melanoma cells but not among normal cells.
When the Akt3 protein was put into cells in conjunction with the mutant B-Raf gene, they were better able to form melanomas compared to cells just containing the mutant B-Raf gene.
"This tells us that you can have a mole but it cannot turn into melanoma without the presence of the Akt3 protein," explained Robertson.
While it is still unclear what brings the B-Raf and Akt3 proteins together, the Penn State researchers say they now have a better understanding of how these two proteins interact to cause melanoma.
The initial mutation of the B-Raf gene helps to create moles, but high levels of B-Raf activity due to the mutation prevents the cells from becoming a melanoma. It is only when the Akt3 protein is present in those cells and communicates with B-Raf that it lower its activity, thereby creating favorable conditions within the mole for cells to multiply, and allow them to turn into a melanoma.
Robertson said the discovery could pave the way for newer and more effective treatments for melanoma.
"We have shown that if we target the two proteins separately, it somewhat inhibits the development of tumors but if we target them together, the development of tumors gets inhibited significantly," he added. "It validates these proteins as key targets for effective melanoma therapy."
Robertson envisions that future physicians could look at blood samples from melanoma patients containing melanoma cells and determine whether the two proteins are in their cells. The patients could then receive drugs that target these proteins to more effectively treat their disease. It would be personalized cancer treatment that would be more effective and less toxic with fewer side effects, the Penn State researcher explained.
"In the search for a cure for melanoma, we are now closer because we know that we need to target these two proteins in order to have a dramatic impact on the development of melanoma," Robertson added.
For patients, this means that in the future, some new drug could target these proteins to treat advanced disease or be added to sunscreen lotion, for instance, that would prevent Akt3 functioning in the cell. It would not only help control a tumor, but also prevent one as well.
Penn State
Melanoma Current Events and Melanoma News RSSChildren's National researchers develop novel anti-tumor vaccine
A novel anti-tumor vaccine for neuroblastoma and melanoma developed by scientists and clinicians at Children's National Medical Center in collaboration with investigators from the University of Iowa is showing significant impact on tumor growth in mice.
Researchers identify mechanism used by gene to promote metastasis in human cancer cells
Virginia Commonwealth University Institute of Molecular Medicine and VCU Massey Cancer Center researchers have discovered how a gene, melanoma differentiation associated gene-9/syntenin (mda-9/syntenin), interacts with an important signaling protein to promote metastasis in human melanoma cells, a discovery that could one day lead to the development of the next generation of anti-metastatic drugs for melanoma and other cancers.
Social class dictates cancer risk
Cervical and lung cancer are more common in poor people while rates of breast cancer and melanoma are higher in the wealthy.
Variant of vitamin D receptor gene linked to melanoma risk
A new analysis indicates an association between a gene involved in vitamin D metabolism and skin cancer. Published in the November 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study suggests that individuals with certain variants in a vitamin D-related gene, called BsmI, may be at an increased risk of developing melanoma.
Wistar researchers invigorate 'exhausted' immune cells
In battles against chronic infections, the body's key immune cells often become exhausted and ineffective. Researchers at The Wistar Institute have found a way to restore vigor to these killer T cells by blocking a key receptor on their surface, findings that may advance the development of new therapies for diseases such as HIV, hepatitis B and C, and cancer.
Nanomedical approach targets multiple cancer genes, shrinks tumors more effectively
Nanoparticles filled with a drug that targets two genes that trigger melanoma could offer a potential cure for this deadly disease, according to cancer researchers.
History of nonmelanoma skin cancer is associated with increased risk for subsequent malignancies
Individuals with a history of nonmelanoma skin cancer (NMSC) are at increased risk for other cancers, according to a study published in the August 26 online issue of the Journal of the National Cancer Institute.
Researchers discover scent of skin cancer
According to new research from the Monell Center, odors from skin can be used to identify basal cell carcinoma, the most common form of skin cancer. The findings, presented at the 236th meeting of the American Chemical Society, may open doors to development of new methods to detect basal cell carcinoma and other forms of skin cancer.
Fish cancer gene linked to pigment pattern that attracts mates
Though skin cancer is deadly to male fish, it also has one perk: The black melanoma splotches arise from attractive natural markings that lure female mates. A new study published in the Proceedings of the National Academy of Sciences this week shows that the melanoma gene can be conserved in swordtail fish because of its beneficial role in sexual selection.
Prototype test for predicting clinical outcome for melanoma patients
Investigators from the Melbourne Center of the international Ludwig Institute for Cancer Research (LICR) and Pacific Edge Biotchnology Ltd today reported that they have developed a test to predict whether a patient will progress rapidly from Stage III melanoma to metastatic Stage IV cancer and death.
More Melanoma Current Events and Melanoma News Articles
 | Melanoma: Prevention, Detection, and Treatment; Second Edition (Yale University Press Health & Wellness) by Catherine M. Poole, IV DuPont Guerry The incidence of melanoma has increased by 2000% since 1930, and one person dies each hour from the disease. This cutting-edge guide provides scientifically accurate information patients and their families need in order to understand melanoma and its treatment and to receive vital reassurance. It is also a resource for those who want information about preventing the disease or finding it early... |
 | 100 Questions & Answers about Melanoma & Other Skin Cancers by Edward F. McClay, Mary-Eileen T. McClay, Jodie Smith This book deals with skin cancer from a doctor's and a patient's... |
 | The Melanoma Book: A Complete Guide to Prevention and Treatment, Including the Early DetectionSelf-Exam Body Map by Howard L. Kaufman From the founder and Co-Director of the renowned Columbia University Melanoma Center, the first comprehensive guide to help you prevent—and survive—a diagnosis of melanoma. The fastest rising form of cancer worldwide, melanoma can strike at any age. Although rates of cure are higher than they used to be, experts often disagree about the best course of treatment and patients face a... |
 | Understanding Melanoma: What You Need to Know by Perry Robins; MD and Maritza Perez; MD Newly updated and now in its third edition, this handbook is written for melanoma patients, their families and friends, health professionals, and every person with an interest in the disease. This valuable book, written by two eminent dermatologist, tells all about melanoma from the moment of diagnosis through state- of-the-art treatments. Honest and straightforward, but reassuring in tone.... |
 | Melanoma Melodrama: A Medical Memoir by Chuck Myer Chuck Myer is an urban planner, freelance writer, playwright, consultant to arts, government, and religious organizations, and an actor and musician. He is described by many as a "Renaissance Man." Melanoma Melodrama is Chuck's graceful and courageous narrative of his battle with cancer. You will learn about a potentially fatal misdiagnosis doctors commonly make for malignant melanoma, about the... |
 | The Definitive Guide to Melanoma by Lowndes Harrison The reassuring tone and clear explanations in this medical handbook provide valuable information to patients and family members struggling to understand a diagnosis of melanoma. Each year, more than 50,000 people in the U.S. learn that they have melanoma, and many of them are either young or elderly. This guide fills the information gap that develops between the initial diagnosis in the doctor's... |
 | What You Really Need to Know about Moles and Melanoma (A Johns Hopkins Press Health Book) by Jill R. Schofield, William A. Robinson Throughout the world, the incidence of malignant melanoma is increasing at an alarming rate. This dramatic rise is largely due to more frequent and prolonged exposure to intense sun, the result of major changes in clothing styles, recreation, and lifestyle (including widespread access to midwinter resort vacations). Significantly, recent scientific studies have shown an increased number of moles... |
 | Pocket Guide to Malignant Melanoma by John Buchan, Dafydd Roberts The ability to diagnose melanomas and ensure that they are properly and swiftly treated can save lives.The latter part of this century has witnessed a rise in the incidence of this life-threatening form of skin cancer, which is linked to sun exposure. Public health campaigns have begun to raise awareness of the problem and people are now seeking medical advice about pigmented lesions. The reader... |
 | Histological Diagnosis of Nevi and Melanoma by Guido Massi, Philip E. LeBoit The interpretation of melanocytic tumors represents one of the most important topics and probably the most difficult challenge in the field of dermatopathology. This text and atlas depicts a broad range of the most important or challenging melanocytic lesions. It illustrates in detail melanocytic neoplasms of diagnostic interest encountered in daily practice. It presents a philosophy of... |
 | From Melanocytes to Melanoma: The Progression to Malignancy Leading researchers and clinicians join forces to explain how malignant melanoma develops from its benign precursor cell type. The authors focus on the molecular mechanisms involved in melanogenesis, in the malignant transformation of melanocytes, and in the further progression of primary melanomas into invasive and metastatic melanomas. They also review recent advances in our understanding of... |
| © 2008 BrightSurf.com |